Verastem, Inc. (NASDAQ: VSTM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Verastem, Inc. (NASDAQ: VSTM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.50 price target on the stock.
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer [Yahoo! Finance]